← Back to Search

Hypofractionation for Endometrial Cancer (SPARTACUSII Trial)

N/A

Waitlist Available

Led By Kathy Han, MD

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 2 years following rt completion

Awards & highlights

SPARTACUSII Trial Summary

This trial is testing a new, shorter radiation treatment for uterine cancer patients who have already had surgery. They hope it will be just as effective as the current standard treatment, but with fewer side effects.

Eligible Conditions

Endometrial Cancer

SPARTACUSII Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 2 years following rt completion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 2 years following rt completion

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 2 years following rt completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acute bowel toxicity

Secondary outcome measures

Acute bowel toxicities

Acute urinary toxicities through CTCAE

Acute urinary toxicities through EPIC

+4 more

SPARTACUSII Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Stereotactic Hypofractionated RadiationExperimental Treatment1 Intervention

Patients randomized to hypofractionation will be treated the stereotactic hypofractionated technique.

Group II: Conventional Fractionation Pelvic RadiationActive Control1 Intervention

Patients randomized to the conventional fractionation arm will be treated with intensity-modulated or volumetric arc therapy technique as per standard protocol.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Hypofractionation

2017

Completed Phase 2

~460

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor

656 Previous Clinical Trials

1,550,572 Total Patients Enrolled

2 Trials studying Endometrial Cancer

45 Patients Enrolled for Endometrial Cancer

Princess Margaret Hospital, CanadaOTHER

119 Previous Clinical Trials

39,009 Total Patients Enrolled

Royal Victoria Hospital, CanadaOTHER

17 Previous Clinical Trials

10,367 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How geographically widespread is this trial's implementation?

"Currently, clinicians at Credit Valley Hospital in Mississauga, Princess Margaret Cancer Centre in Toronto, and Sunnybrook Health Sciences Centre in London are among the 5 recruiting sites for this trial."

Answered by AI

What is the total enrollment of participants in this research?

"Correct. Clinicaltrials.gov records indicate that this study, which went online on July 15th 2021, is currently recruiting participants. 50 individuals need to be recruited from 5 different locations."

Answered by AI

Are there any remaining openings for individuals to participate in this experiment?

"According to clinicaltrials.gov, this clinical trial commenced on July 15th 2021 and is still actively recruiting suitable candidates. The information was last updated by the research team on October 22nd 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II

Dr. Eric Leung 2021. "Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04890912.